Therapeutic Bayesian monitoring of sunitinib in two patients with impaired absorption or elimination.
J Clin Pharm Ther
; 46(4): 1182-1184, 2021 Aug.
Article
em En
| MEDLINE
| ID: mdl-33821517
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
Sunitinib pharmacokinetics can be influenced by the physio-pathological conditions of individual patients. Therapeutic drug monitoring (TDM) helps to optimize efficacy and reduce the risk of adverse effects. We report on the use of Bayesian analysis to optimize sunitinib blood levels. CASESUMMARY:
We describe two patients with risk of sunitinib pharmacokinetic variability due to gastrectomy and ongoing haemodialysis, respectively. TDM and Bayesian estimation allowed maintaining their sunitinib pharmacokinetic profiles within the usual limits. WHAT IS NEW ANDCONCLUSION:
Our analysis showed that Bayesian analysis can be successfully applied for real-time TDM to optimize sunitinib blood levels in patients with major comorbidities.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Monitoramento de Medicamentos
/
Sunitinibe
/
Neoplasias Renais
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article